These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 26440382)
21. The potential of FimH as a novel therapeutic target for the treatment of Crohn's disease. Sivignon A; Bouckaert J; Bernard J; Gouin SG; Barnich N Expert Opin Ther Targets; 2017 Sep; 21(9):837-847. PubMed ID: 28762293 [TBL] [Abstract][Full Text] [Related]
22. Improvement of Aglycone π-Stacking Yields Nanomolar to Sub-nanomolar FimH Antagonists. Schönemann W; Cramer J; Mühlethaler T; Fiege B; Silbermann M; Rabbani S; Dätwyler P; Zihlmann P; Jakob RP; Sager CP; Smieško M; Schwardt O; Maier T; Ernst B ChemMedChem; 2019 Apr; 14(7):749-757. PubMed ID: 30710416 [TBL] [Abstract][Full Text] [Related]
23. FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. Kleeb S; Pang L; Mayer K; Eris D; Sigl A; Preston RC; Zihlmann P; Sharpe T; Jakob RP; Abgottspon D; Hutter AS; Scharenberg M; Jiang X; Navarra G; Rabbani S; Smiesko M; Lüdin N; Bezençon J; Schwardt O; Maier T; Ernst B J Med Chem; 2015 Mar; 58(5):2221-39. PubMed ID: 25666045 [TBL] [Abstract][Full Text] [Related]
24. Kinetic properties of carbohydrate-lectin interactions: FimH antagonists. Scharenberg M; Jiang X; Pang L; Navarra G; Rabbani S; Binder F; Schwardt O; Ernst B ChemMedChem; 2014 Jan; 9(1):78-83. PubMed ID: 24357503 [TBL] [Abstract][Full Text] [Related]
25. The Conformational Variability of FimH: Which Conformation Represents the Therapeutic Target? Eris D; Preston RC; Scharenberg M; Hulliger F; Abgottspon D; Pang L; Jiang X; Schwardt O; Ernst B Chembiochem; 2016 Jun; 17(11):1012-20. PubMed ID: 26991759 [TBL] [Abstract][Full Text] [Related]
28. Fimch antiserum inhibits the adherence of Escherichia coli to cells collected by voided urine specimens of diabetic women. Meiland R; Geerlings SE; Langermann S; Brouwer EC; Coenjaerts FE; Hoepelman AI J Urol; 2004 Apr; 171(4):1589-93. PubMed ID: 15017227 [TBL] [Abstract][Full Text] [Related]
29. Glycosylation changes as important factors for the susceptibility to urinary tract infection. Taganna J; de Boer AR; Wuhrer M; Bouckaert J Biochem Soc Trans; 2011 Jan; 39(1):349-54. PubMed ID: 21265802 [TBL] [Abstract][Full Text] [Related]
30. FimH antagonists: structure-activity and structure-property relationships for biphenyl α-D-mannopyranosides. Pang L; Kleeb S; Lemme K; Rabbani S; Scharenberg M; Zalewski A; Schädler F; Schwardt O; Ernst B ChemMedChem; 2012 Aug; 7(8):1404-22. PubMed ID: 22644941 [TBL] [Abstract][Full Text] [Related]
31. On-cell saturation transfer difference NMR for the identification of FimH ligands and inhibitors. Palmioli A; Sperandeo P; Bertuzzi S; Polissi A; Airoldi C Bioorg Chem; 2021 Jul; 112():104876. PubMed ID: 33845337 [TBL] [Abstract][Full Text] [Related]
32. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Ratliff TL J Urol; 2005 Sep; 174(3):1150. PubMed ID: 16094085 [No Abstract] [Full Text] [Related]
33. Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. Jiang X; Abgottspon D; Kleeb S; Rabbani S; Scharenberg M; Wittwer M; Haug M; Schwardt O; Ernst B J Med Chem; 2012 May; 55(10):4700-13. PubMed ID: 22519985 [TBL] [Abstract][Full Text] [Related]